SCHEMBL629595

SCHEMBL629595

C=CCCCC(F)(F)CN[C@H](C(=O)OC)C(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.36
LMNA P02545 2/20 0.36
CA12 O43570 2/20 0.35
CA14 Q9ULX7 2/20 0.35
NOS3 P29474 2/20 0.34
NOS1 P29475 2/20 0.34
NOS2 P35228 2/20 0.34
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
CA7 P43166 1/20 0.33
CA9 Q16790 1/20 0.33
HPGD P15428 1/20 0.32
MAPT P10636 2/20 0.32
HSD17B10 Q99714 1/20 0.32
GAA P10253 1/20 0.31
USP2 O75604 1/20 0.31
CYP3A4 P08684 1/20 0.31
RECQL P46063 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
TSHR P16473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL629512 0.86 ALDH1A1 (0.32) ALDH1A1LMNAMAPTSMN1; SMN2
SCHEMBL2426658 0.77 ALDH1A1 (0.47) ALDH1A1LMNACA12CA14MEN1
SCHEMBL8229180 0.71 ALDH1A1 (0.51) ALDH1A1LMNAHPGDMAPTUSP2
SCHEMBL733203 0.67 ALDH1A1 (0.40) ALDH1A1CA12CA14MEN1KMT2A
SCHEMBL1274030 0.67 TSHR (0.42) ALDH1A1LMNACA12CA14MEN1
SCHEMBL14773332 0.66 ALDH1A1 (0.44) ALDH1A1LMNACA14MEN1KMT2A
SCHEMBL12197295 0.66 CA14 (0.50) ALDH1A1CA12CA14MEN1KMT2A
SCHEMBL3123664 0.65 ALDH1A1 (0.47) ALDH1A1LMNAMEN1KMT2AHPGD
SCHEMBL10537510 0.65 TSHR (0.42) ALDH1A1CA12CA14MEN1KMT2A
SCHEMBL8231175 0.65 ABCC4 (0.48) ALDH1A1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8314062-B2 Macrocyclic compounds as antiviral agents INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) 2012-11-20 US disclosed
EP-2041159-B8 MACROCYCLIC COMPOUNDS AS ANTIVIRAL AGENTS ANGELETTI P IST RICHERCHE BIO (IT) 2012-02-22 EP disclosed
EP-2041159-B1 MACROCYCLIC COMPOUNDS AS ANTIVIRAL AGENTS ANGELETTI P IST RICHERCHE BIO (IT) 2011-09-28 EP disclosed
US-20090312241-A1 Macrocyclic Compounds as Antiviral Agents ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2009-12-17 US disclosed
EP-2041159-A1 MACROCYCLIC COMPOUNDS AS ANTIVIRAL AGENTS Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. (IT) 2009-04-01 EP disclosed
WO-2007148135-A1 MACROCYCLIC COMPOUNDS AS ANTIVIRAL AGENTS ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2007-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312241-A1 Macrocyclic Compounds as Antiviral Agents ZC3HAV1, ZC3HAV1L, HAVCR2 ALDH1A1 1992/4885LMNA 1334/4885CA12 3624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.